BioMarin Pharmaceutical (HAM:BM8) Float Percentage Of Total Shares Outstanding: 99.74% (As of Jul. 12, 2026)


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
75 GF Score
Price €52.24
GF Value €77.85
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Float Percentage Of Total Shares Outstanding?

BioMarin Pharmaceutical HAM:BM8 -0.27% 75 Float Percentage Of Total Shares Outstanding is 99.74% as of Jul. 12, 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 75/100 and a GF Value™ of €77.85. The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioMarin Pharmaceutical's float shares is 192.77 Mil. BioMarin Pharmaceutical's total shares outstanding is 193.28 Mil. BioMarin Pharmaceutical's float percentage of total shares outstanding is 99.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioMarin Pharmaceutical's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioMarin Pharmaceutical's Institutional Ownership is 67.43%.

HAM:BM8
75GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BioMarin Pharmaceutical's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=192.77/193.28
=99.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.74% mean?
BioMarin Pharmaceutical (HAM:BM8) has a Float Percentage Of Total Shares Outstanding of 99.74% as of Jul. 12, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Float Percentage Of Total Shares Outstanding too high?
BioMarin Pharmaceutical's current Float Percentage Of Total Shares Outstanding is 99.74%. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Float Percentage Of Total Shares Outstanding compare to CYTK and ARWR?
BioMarin Pharmaceutical's Float Percentage Of Total Shares Outstanding of 99.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Float Percentage Of Total Shares Outstanding is 99.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Float Percentage Of Total Shares Outstanding of 99.74%. The stock's GF Value™ is €77.85, compared to a current price of €52.24 — trading 32.9% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.74%. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Float Percentage Of Total Shares Outstanding is 99.74% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €52.24 is trading 32.9% below its estimated GF Value™ of €77.85.

Key valuation signals for HAM:BM8:

  • Float Percentage Of Total Shares Outstanding: 99.74%
  • GF Value™: €77.85 vs. price of €52.24 (32.9% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score

Get the complete analysis for HAM:BM8

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€52.24
Price
€77.85
GF Value